On this episode, we’re discussing a phase III trial that showed improved progression-free survival with VEGFR2 inhibition in certain patients with thyroid cancer. Then, we’ll hear about a report on outcomes of breakthrough COVID-19 infection among fully vaccinated patients with cancer.

Coverage of stories discussed this week on ascopost.com:

Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer

Study Finds Fully Vaccinated Patients With Cancer and Breakthrough COVID-19 Infection Remain at High Risk for Severe Outcomes

To listen to more podcasts from ASCO, visit asco.org/podcasts.